Clinical Trial Update: A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

Pfizer's Phase 3 trial of Vepdegestrant (ARV-471) for advanced/metastatic breast cancer has posted results and the study is listed as not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Vepdegestrant (ARV-471)

Snippet

Sponsor: Pfizer | Conditions: Advanced Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-02-03